| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 212 | 212 | 212 | 299 |
| Research and development | 4,143 | 6,074 | 5,725 | 8,240 |
| General and administrative | 2,994 | 4,195 | 4,157 | 4,125 |
| Total operating expenses | 7,137 | 10,269 | 9,882 | 12,365 |
| Loss from operations | -6,925 | -10,057 | -9,670 | -12,066 |
| Interest income | 462 | 523 | 644 | 986 |
| Gain on sale of joint venture and other income | 22,479 | 118 | 174 | 251 |
| Total other income, net | 22,941 | 641 | 818 | 1,237 |
| Gain (loss) before equity in losses of joint venture | 16,016 | -9,416 | -8,852 | -10,829 |
| Loss on investment in joint venture | 0 | -287 | -587 | -637 |
| Net income (loss) | 16,016 | -9,703 | -9,439 | -11,466 |
| Net unrealized gain (loss) on marketable securities | 7 | -30 | -21 | 240 |
| Other comprehensive gain (loss) | 7 | -30 | -21 | 240 |
| Comprehensive gain (loss) | 16,023 | -9,733 | -9,460 | -11,226 |
| Net income (loss) per common share, basic (in dollars per share) | 0.36 | -0.22 | -0.21 | -0.26 |
| Net income (loss) per common share, diluted (in dollars per share) | 0.36 | -0.22 | -0.21 | -0.26 |
| Weighted-average common shares outstanding, basic (in shares) | 45,058,591 | 44,841,140 | 44,774,602 | 44,593,221 |
| Weighted-average common shares outstanding, diluted (in shares) | 45,058,591 | 44,841,140 | 44,774,602 | 44,593,221 |
Rallybio Corp (RLYB)
Rallybio Corp (RLYB)